Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ronda Crews

Nurse Practitioner, Family Jax Bch, FL Nurse Practitioner

NPI 1326587106 CMS profile 11087051

1370 13Th Ave S Ste 218, Jax Bch, FL 32250

Open in the dashboard

General payments

$155,361

572 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ronda Crews of Jax Bch, FL is reported in the CMS Open Payments database as having received $155,361 across 572 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25,429 100
2024 General $34,044 108
2023 General $39,636 124
2022 General $27,803 117
2021 General $28,449 123

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronda Crews
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Ronda Crews were reported at $25,429. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Ronda Crews Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $28,449 $124 $35–$379 $132
2022 $27,803 $141 $44–$430 $149
2023 $39,636 $154 $49–$476 $160
2024 $34,044 $165 $51–$504 $164
2025 $25,429 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $128,986 332 payments
  2. Amgen Inc. $11,992 66 payments
  3. Actelion Pharmaceuticals US, Inc. $7,928 100 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $5,233 29 payments
  5. Merck Sharp & Dohme Corporation $370 9 payments
  6. Baxter Healthcare $245 12 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $200 1 payment
  8. Philips Electronics North America Corporation $155 8 payments
  9. GlaxoSmithKline, LLC. $89 6 payments
  10. Insmed, Inc. $76 4 payments
  11. Other $86 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $110,945 112 payments
  2. Travel and Lodging $26,888 100 payments
  3. Food and Beverage $12,795 352 payments
  4. Consulting Fee $4,403 3 payments
  5. Education $330 5 payments
Products named General payments · program years 2021–2025
  1. FASENRA $81,313 207 payments
  2. TEZSPIRE Respiratory $45,266 109 payments
  3. TEZSPIRE Inflammation $10,616 61 payments
  4. OPSUMIT $7,796 92 payments
  5. UPTRAVI $6,127 88 payments
  6. WINREVAIR $354 8 payments
  7. BREZTRI $285 8 payments
  8. Hillrom - Life 2000 Ventilation System $245 12 payments
  9. OFEV $214 11 payments
  10. Adempas $200 1 payment
  11. Other $650 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,739

Median for Nurse Practitioner: 389

Drug cost

$2,174,830

Median for Nurse Practitioner: $21,885

Branded share of claims

62.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Uptravi Selexipag Brand 24 $656,908
Opsumit Macitentan Brand 42 $534,086
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 428 $491,617
Ofev Nintedanib Esylate Brand 15 $195,740
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 54 $72,591
Tezspire Tezepelumab-Ekko Brand 11 $49,414
Breo Ellipta Fluticasone/Vilanterol Brand 73 $45,911
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 36 $29,636
Tadalafil Generic 61 $25,553
Spiriva Respimat Tiotropium Bromide Brand 12 $15,106

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$897,537

Of which drugs: $790,017

Medicare patients

494

Average age 77

Services billed

24,749

292 women, 202 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 61%
Ischemic heart disease 55%
Arthritis 53%
Chronic kidney disease 33%
Diabetes 28%
Heart failure 27%
Atrial fibrillation 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, benralizumab, 1 mg J0517 Office 28 4,080 $527,135
Injection, tezepelumab-ekko, 1 mg J2356 Office 12 18,480 $262,882

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
  • AstraZeneca Pharmaceuticals LP $15,446
$15,446 — 4,080
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $11,999
  • Amgen Inc. $156
$12,155 11 18,480
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $2,228
$2,228 24 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $2,209
$2,209 42 —
WINREVAIR
  • Merck Sharp & Dohme Corporation $139
$139 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

572 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record